/CWBR

CWBR Stock - CohBar, Inc.

Q: What is the analyst price target for CWBR?

Analyst price target information is not currently available for CWBR.

Q: What is CWBR's market cap?

Market capitalization information is not currently available for CWBR.

Healthcare|Biotechnology|NASDAQ

$0.41+0.00%

+$0.00 (+0.00%) • Jan 17

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.45

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CWBR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.38

52W High$1.01

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-12,388,297	$-15,408,155	$-13,199,515	$-12,583,034	$-15,334,330
Net Income	$-11,962,119	$-15,408,061	$-14,633,516	$-13,649,136	$-15,705,865
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-4.13	$-6.94	$-8.99	$-9.56	$-11.42

Company Overview

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Visit Website

Earnings History & Surprises

CWBR

Beat Rate

45%

Last 11 quarters

Avg Surprise

-23.9%

EPS vs Estimate

Beats / Misses

5/6

Last 12 quarters

Latest EPS

$-1.39

Q3 2023

EPS Surprise History

Q4 21

+44.4%

$-1.50vs$-2.70

Q1 22

+20.0%

$-1.20vs$-1.50

Q2 22

-33.3%

$-1.20vs$-0.90

Q3 22

+25.0%

$-0.90vs$-1.20

Q4 22

+19.6%

$-0.82vs$-1.02

Q1 23

-244.4%

$-1.30vs$0.90

Q2 23

No data

Q3 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2025	Jan 7, 2025	—	—	—	—
Q4 2024	Dec 27, 2024	—	—	—	—
Q3 2024	Aug 9, 2024	—	—	—	—
Q2 2024	Apr 23, 2024	—	—	—	—
Q1 2024	Feb 12, 2024	—	—	—	—
Q4 2023	Dec 29, 2023	—	—	—	—
Q3 2023	Aug 14, 2023	—	$-1.39	—	—
Q2 2023	May 15, 2023	—	$-0.75	—	—
Q1 2023	Mar 9, 2023	$0.90	$-1.30	-244.4%	✗ MISS
Q4 2022	Nov 8, 2022	$-1.02	$-0.82	+19.6%	✓ BEAT
Q3 2022	Aug 15, 2022	$-1.20	$-0.90	+25.0%	✓ BEAT
Q2 2022	May 16, 2022	$-0.90	$-1.20	-33.3%	✗ MISS
Q1 2022	Mar 29, 2022	$-1.50	$-1.20	+20.0%	✓ BEAT
Q4 2021	Nov 15, 2021	$-2.70	$-1.50	+44.4%	✓ BEAT
Q3 2021	Aug 10, 2021	$-2.10	$-2.40	-14.3%	✗ MISS
Q2 2021	May 17, 2021	$-1.80	$-2.10	-16.7%	✗ MISS
Q1 2021	Mar 30, 2021	$-1.80	$-2.40	-33.3%	✗ MISS
Q4 2020	Nov 16, 2020	$-1.50	$-1.20	+20.0%	✓ BEAT
Q3 2020	Aug 13, 2020	$-1.80	$-2.70	-50.0%	✗ MISS
Q2 2020	May 14, 2020	—	$-1.80	—	—